Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2009, Pages

  Garimella, Pranav S ^b   Fink, Howard A ^c   MacDonald, Roderick ^a   Wilt, Timothy J ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Jr Hospital of Cook County   (United States)

^c VA MEDICAL CENTER   (United States)

Author keywords

Adrenergic alpha antagonists adverse effects; *therapeutic use ; Humans; Male; Naphthalenes adverse effects; *therapeutic use ; Piperazines adverse effects; *therapeutic use ; Prostatic hyperplasia *complications ; Prostatism *drug therapy; etiology ; Randomized controlled trials as topic; Sulfonamides adverse effects; therapeutic use

Indexed keywords

ALPHA 1A ADRENERGIC RECEPTOR; EVIPROSTAT; NAFTOPIDIL; OXYBUTYNIN; PLACEBO; PROPIVERINE; TAMSULOSIN;

AMERICAN UROLOGICAL ASSOCIATION SYMPTOM INDEX; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE SEVERITY; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG WITHDRAWAL; FEASIBILITY STUDY; FOLLOW UP; HEADACHE; HUMAN; HYPOTENSION; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; JAPAN; LOW DRUG DOSE; LOWER URINARY TRACT SYMPTOM; MICTURITION; PARESTHESIA; PHYTOTHERAPY; PROSTATE HYPERTROPHY; QUALITY OF LIFE; REVIEW; SYMPTOM; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 77950130285     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007360.pub2     Document Type: Review

References (30)

1. Gotoh 2005 {published data only} Gotoh M. Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. BJU International 2005;96:581-6.
2. Ikemoto 2003 {published data only} Ikemoto I, Kiyota H, Ohishi Y, Abe K, Goto H, Kishimoto K, Miki K. Usefulness of tamsulosin hydrochloride and naftopidil inpatients with urinary disturbances caused by benign prostatic hyperplasia: A comparative, randomized,two-drug crossover study. International Journal of Urology 2003;10:587-94.
3. Maruyama 2006 {published data only} Maruyama O, Kawachi Y, Hanzawa K, Koizumi K, Yamashita R, Sugimura S, Honda S, Sugiyama Y, Saitoh T, Noto K. Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study. International Journal of Urology 2006;13:1280-5.
4. Momose 2007 {published data only} Momose H, Hosokawa Y, Kishino T, Ono T, Oyama N. Crossover comparison study on the therapeutic effects of tamsulosin hydrochloride and naftopidil in lower urinary tract symptoms associated with benign prostatic hyperplasia. Drugs of Today 2007; 43(suppl A):1-10.
5. Nishinio 2006 {published data only} Nishinio Y, Masue T, Miwa K, Takahashi Y, Ishihara S, Deguchi T. Comparison of twoa1-adrenoceptor antagonists,naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. BJU International 2006;97:747-51.
6. Ukimura 2008 {published data only} Ukimura O, Kanazawa M, Fujihara A, Kamoi K, Okihara K, Miki T and Kyoto Prefectural University of Medicine Benign Prostatic Hypertrophy Research Group. Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom: A prospective randomized controlled study. International Journal of Urology 2008;15:1049-54.
7. Yamanishi 2004 {published data only} Yamanishi T. Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha -blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia. International Journal of Urology 2004;11:501-9.
8. Yokoyama 2006 {published data only} Yokoyama T, Kumon H, Nasu Y, Takamoto H, Watanabe T. Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: Aprospective, randomized controlled study. International Journal of Urology 2006;13:932-8.
9. Awa 2008 {published data only} Awa Y, Suzuki H, Hamano S, Okano T, Sakurayama Y, Ohki T, Egoshi K, Ota S, Mori I, Ichikawa T. Clinical effect of alpha 1D/A adrenoceptor inhibitor naftopidil on benign prostatic hyperplasia: an international prostate symptom score and King's Health Questionnaire assessment. International Journal of Urology 2008;15(8):709-15.
10. Furuya 2005 {published data only} Furuya R. Hisasue S. Ogura H. Furuya S. Masumori N. Itoh N. Tsukamoto T. Ejaculatory disorder by alpha-1 adrenoceptor antagonist in patients with benign prostatic hyperplasia; retrospective comparison between naftopidil and tamsulosin. Hinyokika Kiyo - Acta Urologica Japonica 2005;51(11):763-6.
11. Hayashi 2002 {published data only} Hayashi T, Sakai Y, Saito K, Arai G, Hyochi N, Suzuki M, Masuda H, Kawakami S, Okuno T, Kobayashi T, Kageyama Y, Kihara K. A comparative study assessing clinical effects of naftopidil and tamsulosin hydrochloride on benign prostatic hyperplasia. Hinyokika Kiyo 2002;48(1):7-11.
12. Ju 2002 {published data only} Ju XB, Wu HF, Su JT. The clinical efficacy of Naftopidil tablet in the treatment of benign prostatic hyperplasia. Zhong Hua NanKe Xue 2002;8(4):286-8.
13. Kaplan 2005 {published data only} Kaplan SA. Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia. Journal of Urology 2005;174(3): 1011.
14. Kosugi 2007 {published data only} Kosugi S. Ikemoto I. Furuta A. Shimomura T. Kiyota H. Suzuki Y. Kishimoto K. Egaway S. Torii S. Shirai H. Takeuchi H. Abe K. A comparative study assessing clinical effects of naftopidil and tamsulosin hydrochloride on benign prostatic hyperplasia with overactive bladder. Nippon Hinyokika Gakkai Zasshi - Japanese Journal of Urology 2007;98(5):691-9.
15. Li 2007 {published data only} Li NC, Wu SL, Jin J, Qiu SP, Kong CZ, Song YS, Ye ZQ, Sun G, Sun YH, Sun YC, Wang XF, Na YQ. Comparison of different drugs on the treatment of benign prostate hyperplasia. Chung-Hua Wai Ko Tsa Chih [Chinese Journal of Surgery] 2007;45(14):947-50.
16. Masumori 2007 {published data only} Masumori N, Hashimoto J, Itoh N, Tsukamoto T, The Sapporo Medical University Naftopidil Study Group. Short-term efficacy and long-term compliance/treatment failure of the α1 blocker naftopidil for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Scandinavian Journal of Urology and Nephrology 2007;41:422-429.
17. Sugino 2003 {published data only} Sugino Y, Fukuzawa S, Takeuchi H, Taki Y, Hashimura T, Soeda T, Araki I. Clinical effects of naftopidil on nocturia associated with benign prostatic hyperplasia. Hinyokika Kiyo - Acta Urologica Japonica 2003;49(8):445-9.
18. Takahashi 2006 {published data only} Takahashi S, Tajima A, Matsushima H, Kawamura T, Tominaga T, Kitamura T. Clinical efficacy of an alpha1A/D-adrenoceptor blocker (naftopidil) on overactive bladder symptoms in patients with benign prostatic hyperplasia. Internal Journal of Urololgy 2006; 13(1):15-20.
19. Yamaguchi 1992 {published data only} Yamaguchi O, Fukaya Y, Shiraiwa Y, Kaneko S, Yachiku S, Yasuda K, Shimazaki J, Takagi R, Sato S, Kondo A, Miyake K, Taira N. Clinical Evaluation of Naftopidil (KT-611) on Urinary Obstruction Caused by Benign Prostatic Hypertrophy: Double-Blind Comparative Study Compared with Prazosin Hydrochloride [Zenritsusen Hidaisho ni Tomonau Hainyo Shogai ni Taisuru Nafutopijiru (KT-611) no Rinsho Hyoka: Ensan Purazoshin o Taishoyaku to Shita Niju Moken Hikaku Shiken]. Rinsho Iyaku [Journal of Clinical Therapeutics andMedicines] 1992;8(3):699-722.
20. Yasuda 1994 {published data only} Yasuda K, Yamanishi T, Tojo M, Nagashima K, Akimoto S, Shimazaki J. Effect of naftopidil on urethral obstruction in benign prostatic hyperplasia: assessment by urodynamic studies. Prostate 1994;25(1):46-52.
21. Andersson 2007 Andersson KE. LUTS Treatment: Future Treatment Options. Neurourology and Urodynamics 2007;26:934-47.
22. AUA Guideline 2003 AUA Guideline on the Management of Benign Prostatic Hyperplasia: Diagnosis and Treatment Recommendations. 2003.
23. DerSimonian 1986 DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clinical Trials 1986, (7):177-88.
24. Helfand 2007 Helfand M, Muzyk T, Garzotto M. Comparative Effectiveness Review. Benign Prostatic Hyperplasia (BPH) Management in Primary Care- Screening and Therapy. Department of Veteran Affairs HSR&D. Final report February 2007.
25. Higgins 2003 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;323:557-60.
26. Kojima 2006 Kojima Y, Sasaki S, Shinoura H, Hayashi Y, Tsujimoto G, Kohri K. Quantification of alpha1-adrenoceptor subtypes by real-time RTPCR and correlation with age and prostate volume in benign prostatic hyperplasia patients. Prostate 2006;66(7):761-7.
27. Lepor 2006 Lepor H. The Evolution of Alpha blockers for the Treatment of Benign Prostatatic Hyperplasia. Reviews in Urology 2006;8(suppl 4):S3-S9.
28. Madersbacher 2004 Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JMCH. EAU 2004 Guidelines on Assessment, Therapy and Follow-Up of Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction (BPH Guidelines). European Urology 2004;46:547-54.
29. Review Manager 2008 Review Manager (RevMan). Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration 2008.
30. Schulz 1995 Schulz KF, Chalmers I, Hayes RJ, et al.Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Journal of the American Medical Association 1995;273:408.